Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sodium chloride + magnesium chloride + sodium gluconate + sodium acetate + potassium chloride is an intravenous balanced crystalloid electrolyte solution used for extracellular fluid and electrolyte replacement. It is formulated to approximate extracellular fluid composition and works by expanding intravascular and interstitial volume while supplying sodium, potassium, magnesium, chloride, acetate, and gluconate; acetate and gluconate are metabolized to bicarbonate precursors and contribute an alkalinizing effect. The combination is marketed in products such as Plasma-Lyte A and Plasma-Lyte 148 and is used for acute extracellular fluid volume loss, moderate blood loss, shock, and general hydration/electrolyte replacement in adults and pediatric patients. It is a pharmaceutical inorganic salt combination rather than a biologic or target-directed molecular therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium chloride + magnesium chloride + sodium gluconate + sodium acetate + potassium chloride.